Isolagen Inc - Current report filing (8-K)
August 05 2008 - 3:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): AUGUST 5, 2008
ISOLAGEN, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-31564
|
|
87-0458888
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
405 EAGLEVIEW BLVD., EXTON, PA
|
|
19341
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(484) 713-6000
|
NOT APPLICABLE
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 8.01 Other Events
On August 5, 2008, Isolagen, Inc., a Delaware corporation (the Company), issued a press release announcing results
from two pivotal, Phase III clinical studies of the Isolagen Therapy for the treatment of nasolabial folds, or
wrinkles. Isolagen also announced that an investor conference call is to be held on Wednesday, August 6, 2008 at 8:00
a.m. Eastern time to discuss results from its Phase III studies. A copy of the press release is attached as Exhibit
99.1 hereto, the contents of which are incorporated herein by reference.
Item 9.01 Financial Statement and Exhibits.
(a) Not applicable.
(b) Not applicable.
(c) Not applicable.
(d) Exhibits.
|
99.1
|
|
Press release dated August 5, 2008
|
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
ISOLAGEN, INC.
Date: August 5, 2008
By:_
/
s/ Todd J. Greenspan
Todd J. Greenspan,
Chief Financial Officer
2
Isolagen (AMEX:ILE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Isolagen (AMEX:ILE)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Isolagen (American Stock Exchange): 0 recent articles
More Isolagen Inc News Articles